Perez V, et al. - Researchers assessed the implementation of a strategy for the management of nonmetastatic unilateral retinoblastoma in children based on standardized diagnostic and treatment criteria. Among the registered children, 52.5% were female. The median age was 22 months; age range, 3-100 months. Findings suggested an effectiveness of adjuvant therapy for high-risk unilateral retinoblastoma but was seen to be toxic. Experts noted the feasibility of neoadjuvant chemotherapy for buphthalmus. The 3-year probability of event-free survival was 0.97, and the probability of overall survival was 0.98, with a median follow-up of 46 months.